Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Shares of Amgen started crashing in early November and didn’t improve when the company released data from a Phase 2 clinical trial for its weight-loss candidate MariTide. That plunge has set the ...

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a phase 2 clinical trial for its weight-loss candidate MariTide.

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

“In our mind, Boehringer looks to be the third large pharma company that can actually enter the obesity space with a very differentiated molecule ... In that sense, VK-2735 could compete with MariTide ...

Results from a double-blind, dose-ranging phase 2 study of maridebart cafraglutide (MariTide, Amgen) were presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.